Preparation and Physicochemical Characterizations of Niosomal Benzoyl Peroxide and Clindamycin Phosphate Formulation for Acne Vulgaris

IF 2.7 4区医学 Q2 PHARMACOLOGY & PHARMACY

Journal of Pharmaceutical Innovation Pub Date : 2024-01-11 DOI:10.1007/s12247-024-09807-z

Maryam Rezaeizadeh, Amir Eskanlou, Abbas Pardakhty, Mostafa Pournamdari, Mohammad Daneshpajooh

{"title":"Preparation and Physicochemical Characterizations of Niosomal Benzoyl Peroxide and Clindamycin Phosphate Formulation for Acne Vulgaris","authors":"Maryam Rezaeizadeh, Amir Eskanlou, Abbas Pardakhty, Mostafa Pournamdari, Mohammad Daneshpajooh","doi":"10.1007/s12247-024-09807-z","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>This study aimed to prepare and characterize a topical niosomal formulation of benzoyl peroxide (BP) and clindamycin phosphate (CMP) for the treatment of acne vulgaris.</p><h3>Methods</h3><p>Different combinations of Polyoxyethylene Alkyl Ethers (Brij), sorbitan esters (Span), and their ethoxylated derivatives (Tween), and cholesterol were used to produce the niosomes. Encapsulation, release, chemical and physical stabilities of the prepared formulations were studied.</p><h3>Results</h3><p>The studied niosomes exhibited high physical stability, as evidenced by unchanged size distribution over a six-month storage period. Formulations composed of Brij-52 combined with 50 mol% of cholesterol showed the highest encapsulation efficiency for both CMP (81.5 ± 7.4%) and BP (95.6 ± 3.5%). The release rate of CMP was found to be greater than BP.</p><h3>Conclusions</h3><p>It was concluded that niosomes could serve as stable carriers for topical drug delivery of CMP and BP, specifically in the treatment of acne vulgaris.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"19 1","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2024-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Innovation","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12247-024-09807-z","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

This study aimed to prepare and characterize a topical niosomal formulation of benzoyl peroxide (BP) and clindamycin phosphate (CMP) for the treatment of acne vulgaris.

Methods

Different combinations of Polyoxyethylene Alkyl Ethers (Brij), sorbitan esters (Span), and their ethoxylated derivatives (Tween), and cholesterol were used to produce the niosomes. Encapsulation, release, chemical and physical stabilities of the prepared formulations were studied.

Results

The studied niosomes exhibited high physical stability, as evidenced by unchanged size distribution over a six-month storage period. Formulations composed of Brij-52 combined with 50 mol% of cholesterol showed the highest encapsulation efficiency for both CMP (81.5 ± 7.4%) and BP (95.6 ± 3.5%). The release rate of CMP was found to be greater than BP.

Conclusions

It was concluded that niosomes could serve as stable carriers for topical drug delivery of CMP and BP, specifically in the treatment of acne vulgaris.

Abstract Image

查看原文本刊更多论文

用于治疗痤疮的过氧化苯甲酰和磷酸克林霉素(Niosomal Benzoyl Peroxide and Clindamycin Phosphate)配方的制备和理化特性分析

方法用聚氧乙烯烷基醚（Brij）、山梨醇酯（Span）及其乙氧基化衍生物（吐温）和胆固醇的不同组合来制备含氧体。研究结果显示，所研究的niosomes具有很高的物理稳定性，其大小分布在六个月的储存期内保持不变。由 Brij-52 和 50 mol% 胆固醇组成的制剂对 CMP（81.5 ± 7.4%）和 BP（95.6 ± 3.5%）的包封效率最高。结论：niosomes 可以作为 CMP 和 BP 局部给药的稳定载体，特别是在治疗寻常痤疮方面。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Pharmaceutical Innovation PHARMACOLOGY & PHARMACY-

CiteScore

3.70

自引率

3.80%

发文量

审稿时长

>12 weeks

期刊介绍： The Journal of Pharmaceutical Innovation (JPI), is an international, multidisciplinary peer-reviewed scientific journal dedicated to publishing high quality papers emphasizing innovative research and applied technologies within the pharmaceutical and biotechnology industries. JPI''s goal is to be the premier communication vehicle for the critical body of knowledge that is needed for scientific evolution and technical innovation, from R&D to market. Topics will fall under the following categories: Materials science, Product design, Process design, optimization, automation and control, Facilities; Information management, Regulatory policy and strategy, Supply chain developments , Education and professional development, Journal of Pharmaceutical Innovation publishes four issues a year.